Skip to content

MaxCyte MXCT Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$34.15K
Repligen logo
RepligenRGEN
-$13.76M
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
-$100K
Distribution Solutions Group, Inc. logo
Distribution Solutions Group, Inc.DSGR
-$80K-633%

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: MaxCyte’s 10-K, filed March 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's gain/loss on asset sales?
MaxCyte (MXCT) reported gain/loss on asset sales of -$155K in Q4 2025.
How has MaxCyte's gain/loss on asset sales changed year-over-year?
MaxCyte's gain/loss on asset sales increased by 61.2% year-over-year, from -$399K to -$155K.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.